EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
(NASDAQ: EYPT) Delayed: 3.99 +0.54 (15.65%)
Previous Close $3.45    52 Week High $ 
Open $3.57    52 Week Low $ 
Day High $4.01    P/E N/A 
Day Low $3.50    EPS $ 
Volume 6,975,491